Abbott: Biointerface Patent Lacks Written Description Support
ALEXANDRIA, Va. — In an April 21 petition for inter partes review (IPR) filed with the Patent Trial and Appeal Board, Abbott Diabetes Care Inc. maintains that six claims of a...To view the full article, register now.
Already a subscriber? Click here to view full article